Impossible Foods, which makes plant-based nuggets, burgers and patties, is reportedly laying off 20% of its staff, Bloomberg reported first. TechCrunch reports: According to the story, the 12-year-old company currently employs about 700 workers, which could then affect over 100 employees. This comes as the company made a 6% reduction in its workforce last October. While we know layoffs can happen anytime, it seems like the company was doing well. Earlier this month, the Redwood City, California-based company reported a year of record sales that included over 50% dollar sales growth in 2022. The company also touted that its Impossible Beef product was "the best-selling product by volume of any plant-based meat brand in the U.S."

Months before that, CEO Peter McGuinness said in an interview with Bloomberg Technology that the company had a strong balance sheet, good cash flow and growth of between 65% to 70%. In total, Impossible raised $1.9 billion in venture capital, according to Crunchbase data. The last time the company raised capital was a $500 million Series H round in November 2021, and it was at that time that the company was valued at $7 billion. [...] Impossible is not the only plant-based meat alternative company to make layoffs in recent months. In a regulatory filing made last October, Beyond Meat said it planned to lay off about 200 employees, or 19% of its workforce, as part of cost-saving measures as sales were slumping.

The New York Times looks at the AbbVie's anti-inflammatory drug Humira and their "savvy but legal exploitation of the U.S. patent system." Though AbbVie's patent was supposed to expire in 2016, since then it's maintained a monopoly that generated $114 billion in revenue by using "a formidable wall of intellectual property protection and suing would-be competitors before settling with them to delay their product launches until this year." AbbVie did not invent these patent-prolonging strategies; companies like Bristol Myers Squibb and AstraZeneca have deployed similar tactics to maximize profits on drugs for the treatment of cancer, anxiety and heartburn. But AbbVie's success with Humira stands out even in an industry adept at manipulating the U.S. intellectual-property regime.... AbbVie and its affiliates have applied for 311 patents, of which 165 have been granted, related to Humira, according to the Initiative for Medicines, Access and Knowledge, which tracks drug patents. A vast majority were filed after Humira was on the market.

Some of Humira's patents covered innovations that benefited patients, like a formulation of the drug that reduced the pain from injections. But many of them simply elaborated on previous patents. For example, an early Humira patent, which expired in 2016, claimed that the drug could treat a condition known as ankylosing spondylitis, a type of arthritis that causes inflammation in the joints, among other diseases. In 2014, AbbVie applied for another patent for a method of treating ankylosing spondylitis with a specific dosing of 40 milligrams of Humira. The application was approved, adding 11 years of patent protection beyond 2016.

AbbVie has been aggressive about suing rivals that have tried to introduce biosimilar versions of Humira. In 2016, with Amgen's copycat product on the verge of winning regulatory approval, AbbVie sued Amgen, alleging that it was violating 10 of its patents. Amgen argued that most of AbbVie's patents were invalid, but the two sides reached a settlement in which Amgen agreed not to begin selling its drug until 2023.

Over the next five years, AbbVie reached similar settlements with nine other manufacturers seeking to launch their own versions of Humira. All of them agreed to delay their market entry until 2023.
A drug pricing expert at Washington University in St. Louis tells the New York Times that AbbVie and its strategy with Humira "showed other companies what it was possible to do."

But the article concludes that last year such tactics "became a rallying cry" for U.S. lawmakers "as they successfully pushed for Medicare to have greater control over the price of widely used drugs that, like Humira, have been on the market for many years but still lack competition."

segaboy81 shares a report from Neowin: What do you get when the world's largest CRM breaks into the research industry and leverages AI to build their products? You get ProGen, a new AI system that can make artificial enzymes from scratch that can work just as well as real ones found in nature. ProGen was made by Salesforce Research (yes, that Salesforce) and uses language processing to learn about biology. In short, ProGen takes amino acid sequences and turns them into proteins....

"The artificial designs are better than ones made by the normal process," said James Fraser, a scientist involved in the project. "We can now make specific types of enzymes, like ones that work well in hot temperatures or acid."

To make ProGen, the scientists at Salesforce fed the system amino acid sequences from 280 million different proteins. The AI system quickly made a staggering one million protein sequences, of which 100 were picked to test. Out of these, five were made into actual proteins and tested in cells. That's just 0.0005% of the generated results....

The code for ProGen is available on Github for anyone who wants to try it (or add to it)
The project shows "how generative AI can lead to potential solutions for addressing challenges in human disease and the environment," argues a statement form Salesforce.

More details from New Scientist: The AI, called ProGen, works in a similar way to AIs that can generate text. ProGen learned how to generate new proteins by learning the grammar of how amino acids combine to form 280 million existing proteins. Instead of the researchers choosing a topic for the AI to write about, they could specify a group of similar proteins for it to focus on. In this case, they chose a group of proteins with antimicrobial activity.

The researchers programmed checks into the AI's process so it wouldn't produce amino acid "gibberish", but they also tested a sample of the AI-proposed molecules in real cells. Of the 100 molecules they physically created, 66 participated in chemical reactions similar to those of natural proteins that destroy bacteria in egg whites and saliva. This suggested that these new proteins could also kill bacteria. The researchers selected the five proteins with the most intense reactions and added them to a sample of Escherichia coli bacteria. Two of the proteins destroyed the bacteria.

The researchers then imaged them with X-rays. Even though their amino acid sequences were up to 30% different from any existing proteins, their shapes almost matched naturally occurring proteins. James Fraser at the University of California, San Francisco, who was part of the team, says it was not clear from the outset that the AI could work out how to change the amino acid sequence so much and still produce the correct shape.... He was surprised to have found a well-functioning protein in the first relatively small fraction of all the ProGen-generated proteins that they tested.

An anonymous reader quotes a report from MIT Technology Review: Eight years ago, a patient lost her power of speech because of ALS, or Lou Gehrig's disease, which causes progressive paralysis. She can still make sounds, but her words have become unintelligible, leaving her reliant on a writing board or iPad to communicate. Now, after volunteering to receive a brain implant, the woman has been able to rapidly communicate phrases like "I don't own my home" and "It's just tough" at a rate approaching normal speech. That is the claim in a paper published over the weekend on the website bioRxiv by a team at Stanford University. The study has not been formally reviewed by other researchers. The scientists say their volunteer, identified only as "subject T12," smashed previous records by using the brain-reading implant to communicate at a rate of 62 words a minute, three times the previous best. [...] People without speech deficits typically talk at a rate of about 160 words a minute. Even in an era of keyboards, thumb-typing, emojis, and internet abbreviations, speech remains the fastest form of human-to-human communication.

The brain-computer interfaces that [co-lead author Krishna Sehnoy's] team works with involve a small pad of sharp electrodes embedded in a person's motor cortex, the brain region most involved in movement. This allows researchers to record activity from a few dozen neurons at once and find patterns that reflect what motions someone is thinking of, even if the person is paralyzed. In previous work, paralyzed volunteers have been asked to imagine making hand movements. By "decoding" their neural signals in real time, implants have let them steer a cursor around a screen, pick out letters on a virtual keyboard, play video games, or even control a robotic arm. In the new research, the Stanford team wanted to know if neurons in the motor cortex contained useful information about speech movements, too. That is, could they detect how "subject T12" was trying to move her mouth, tongue, and vocal cords as she attempted to talk?

These are small, subtle movements, and according to Sabes, one big discovery is that just a few neurons contained enough information to let a computer program predict, with good accuracy, what words the patient was trying to say. That information was conveyed by Shenoy's team to a computer screen, where the patient's words appeared as they were spoken by the computer. [...] The current system already uses a couple of types of machine learning programs. To improve its accuracy, the Stanford team employed software that predicts what word typically comes next in a sentence. "I" is more often followed by "am" than "ham," even though these words sound similar and could produce similar patterns in someone's brain. Adding the word prediction system increased how quickly the subject could speak without mistakes.

An anonymous reader quotes a report from the BBC: It was landing at Singapore's international airport a decade ago that sparked Shara Ticku's idea to create a lab-grown alternative to palm oil. "In 2013 I flew to Singapore, and when I landed I had to wear a mask," says the boss of US tech firm C16 Biosciences. "The air was toxic because they were burning the rainforest in Indonesia." Indonesian farmers, who were clearing land for palm oil and other crops, were blamed for the fires and the smoke that drifted across the sea to Singapore. Fast forward to today, and her business has just commercially released an alternative to palm oil that is created from yeast cells.

Palm oil remains the world's most-produced vegetable oil, accounting for 40% of the total, according to the World Wide Fund for Nature (WWF). [...] The widely-documented problem with this usage is that this demand for palm oil has led to significant deforestation in areas where oil palm trees can grow -- low-lying, hot, wet areas near the equator. The use of this land for palm oil cultivation, 85% of which is in Indonesia and Malaysia, has increased almost nine-fold from 3.3 million hectares (eight million acres) in 1970 to 28.7 million hectares in 2020. In financial terms, one report valued the worldwide palm oil industry at $62.3 billion in 2021. And such is the continuing growth in demand, this figure is expected to increase to $75.7 billion by 2028.

To try to reduce the world's reliance on palm oil, Ms Ticku, who was formerly an investment banker, and her co-founders set up C16 Biosciences in New York City in 2018. Backed by multi-million dollar funding from Microsoft founder Bill Gates, the company has spent the past four years developing and finessing their product, which is called Palmless. They grow a strain of yeast that naturally produces an oil with very similar properties to palm, which they harvest. The yeast is fed on sugars from sugar cane plants grown on land already used for arable farming. "Our process takes less than seven days from start to finish," says a spokeswoman for C16 Biosciences. "For a traditional oil palm tree, the oil wouldn't be ready to harvest until years after the seed is planted, and most trees don't reach peak production until seven years later." She adds that the company is now "actively collaborating on partnerships in the beauty and home categories -- for example, moisturizers, nourishing oils, soaps and cancels". "[And] we plan to enter into food in 2024." Chris Chuck, professor of bioprocess engineering at the University of Bath, leads another team that has created its own yeast-sourced alternative. "After hundreds of generations of yeast, and years of trial and error, they arrived at a unique strain called metschnikowia pulcherrima, or MP for short," reports the BBC. "MP is said to be hardy and not fussy what it eats. It can be fed on grass and food waste. And at the point of harvesting, its cells are full of oil. Even the leftover yeast cell biomass need not go to waste. It can be used for other products, for example creating a substitute for soya protein."

Prof Chuck says the aim is for the oil to be as sustainable as possible. "In the best case scenarios we've modeled," he says, "it could be even just a couple of percent of the greenhouse gas emissions from palm oil grown in Indonesia or Malaysia."

"In Boston labs, old, blind mice have regained their eyesight, developed smarter, younger brains and built healthier muscle and kidney tissue," reports CNN: On the flip side, young mice have prematurely aged, with devastating results to nearly every tissue in their bodies. The experiments show aging is a reversible process, capable of being driven "forwards and backwards at will," said anti-aging expert David Sinclair, a professor of genetics in the Blavatnik Institute at Harvard Medical School and codirector of the Paul F. Glenn Center for Biology of Aging Research. Our bodies hold a backup copy of our youth that can be triggered to regenerate, said Sinclair, the senior author of a new paper showcasing the work of his lab and international scientists.

The combined experiments, published for the first time Thursday in the journal Cell, challenge the scientific belief aging is the result of genetic mutations that undermine our DNA, creating a junkyard of damaged cellular tissue that can lead to deterioration, disease and death. "It's not junk, it's not damage that causes us to get old," said Sinclair, who described the work last year at Life Itself, a health and wellness event presented in partnership with CNN. "We believe it's a loss of information — a loss in the cell's ability to read its original DNA so it forgets how to function — in much the same way an old computer may develop corrupted software. I call it the information theory of aging."

Jae-Hyun Yang, a genetics research fellow in the Sinclair Lab who coauthored the paper, said he expects the findings "will transform the way we view the process of aging and the way we approach the treatment of diseases associated with aging."
While Sinclair is now testing "genetic resets" in primates, the article warns that "decades could pass before any anti-aging clinical trials in humans begin, get analyzed and, if safe and successful, scaled to the mass needed for federal approval."

But Sinclair suggests damage could probably also be repaired through healthy behaviors like exercise and sufficient sleep, social support and lower stress levels, eating less often and focusing on plants.

Thanks to long-time Slashdot reader 192_kbps for sharing the story.

An anonymous reader quotes a report from MIT Technology Review: A small biotech company claims it has used a technology called reprogramming to rejuvenate old mice and extend their lives, a result suggesting that one day older people could have their biological clocks turned back with an injection -- literally becoming younger. The life-extension claim in rodents, made by Rejuvenate Bio, a San Diego biotech company, appears in a preprint paper on the website BioRxiv and hasn't been peer reviewed.

Noah Davidsohn, chief scientific officer of Rejuvenate, says the company used gene therapy to add three powerful reprogramming genes to the bodies of mice that were equivalent in age to human 77-year-olds. After the treatment, their remaining life span was doubled, the company says. Treated mice lived another 18 weeks, on average, while control mice died in nine weeks. Overall, the treated mice lived about 7% longer. Although the increase in lifespan was modest, the company says the research provides a demonstration of age reversal in an animal. "This is a powerful technology, and here is the proof of concept," says Davidsohn. "I wanted to show that it's actually something we can do in our elderly population."

Scientists not connected to the company called the study an exciting landmark but cautioned that whole-body rejuvenation using gene therapy remains a poorly understood concept with huge risks. "It's a beautiful intellectual exercise, but I would shy away from doing anything remotely similar to a person," says Vittorio Sebastiano, a professor at Stanford University. One risk is that the powerful programming process can cause cancer. Such an effect is often seen in mice. Even so, the chance that reprogramming could be an elixir of youth has led to a research and investment boom. One company, Altos Labs, says it has raised over $3 billion. "Far more information will be needed to learn exactly what changes the reprogramming genes cause in the mice, and researchers say other groups will need to repeat the experiment before they are convinced," adds the report.

"Sebastiano says the life-extension effect reported by Rejuvenate could be due to changes in a single organ or group of cells, rather than a general mouse-wide rejuvenation effect. Among other shortfalls in its research, Rejuvenate did not carefully document which and how many cells were changed by the genetic treatment."

"Wheat now provides 20% of the calories consumed by humans every day," writes the Guardian. Unfortunately, "Thanks to human-induced global heating, our planet faces a future of increasingly severe heat waves, droughts and wildfires that could devastate harvests in future, triggering widespread famine in their wake.

"But the crisis could be averted thanks to remarkable research now being undertaken by researchers at the John Innes Centre in Norwich." They are working on a project to make wheat more resistant to heat and drought. Such efforts have proved to be extremely tricky but are set to be the subject of a new set of trials in a few weeks as part of a project in which varieties of wheat — created, in part, by gene-editing technology — will be planted in field trials in Spain. The ability of these varieties to withstand the heat of Iberia will determine how well crop scientists will be able to protect future arable farms from the worst vicissitudes of climate change, and so bolster food production for the Earth's billions, says the John Innes Centre team....

"A key tool in this work was gene editing, which allowed us to make precise changes in wheat DNA. Without it, we would still be struggling with this. It has made all the difference."
This was an especially difficult struggle because wheat genetics includes multiple ancestral genomes, the article points.

Thanks to long-time Slashdot reader schwit1 for submitting the story.

The US has approved use of the world's first vaccine for honey bees. The BBC reports: The US Department of Agriculture (USDA) approved a conditional license for the vaccine this week, according to the biotech firm behind its development. It was engineered to prevent fatalities from American foulbrood disease, a bacterial condition known to weaken colonies by attacking bee larvae. [...] American foulbrood disease poses a challenge for beekeepers as it is highly contagious and has no cure. The only treatment method requires burning the colony of infected bees along with the hives and equipment and treating nearby colonies with antibiotics.

The new vaccine contains an inactive version of the bacteria that causes American foulbrood disease, Paenibacillus larvae, according to Dalan Animal health. The bacteria are incorporated into royal jelly feed given by worker bees to the queen bee, which then ingests the feed and keeps some of the vaccine in her ovaries, according to the biotech firm, which specializes in insect health and immunology. It says this gives bee larvae immunity to the disease as they hatch and reduces death from the illness. [...] Dalan plans to distribute the vaccine "on a limited basis" to commercial beekeepers and said the product would probably be available for purchase in the US this year.

"A teenage girl's incurable cancer has been cleared from her body," reports the BBC, "in the first use of a revolutionary new type of medicine...." Doctors at Great Ormond Street Hospital used "base editing" to perform a feat of biological engineering to build her a new living drug. Six months later the cancer is undetectable, but Alyssa is still being monitored in case it comes back.

Alyssa, who is 13 and from Leicester, was diagnosed with T-cell acute lymphoblastic leukaemia in May last year.... Her cancer was aggressive. Chemotherapy, and then a bone-marrow transplant, were unable to rid it from her body.... The team at Great Ormond Street used a technology called base editing, which was invented only six years ago [which] allows scientists to zoom to a precise part of the genetic code and then alter the molecular structure of just one base, converting it into another and changing the genetic instructions. The large team of doctors and scientists used this tool to engineer a new type of T-cell that was capable of hunting down and killing Alyssa's cancerous T-cells....

After a month, Alyssa was in remission and was given a second bone-marrow transplant to regrow her immune system.... Alyssa is just the first of 10 people to be given the drug as part of a clinical trial.
Her mother said that a year ago she'd been dreading Christmas, "thinking this is our last with her". But it wasn't.

And the BBC adds that applying the technology to cancer "only scratches the surface of what base editing could achieve.... There are already trials of base editing under way in sickle-cell disease, as well as high cholesterol that runs in families and the blood disorder beta-thalassemia."

This week the Atlantic published its list of "the 10 Most Promising Breakthrough Innovations of 2022."

"We didn't just get one 'unheard-of' cancer breakthrough; we got several in one year...." Is death reversible? It was this year for several pigs (or, at least, for their organs). By pumping an experimental substance into the veins and arteries of animals that had been lying deceased for an hour, Yale researchers got their hearts to start beating again. The technology is "very far away from use in humans," Stephen Latham, a bioethicist at Yale University, told The New York Times. In the short term, scientists said, they hope that their research could help doctors preserve the organs of the recently deceased for use in transplants. But the longer-term implications of the experiment can't be ignored: If we have the power to reanimate the heart or other organs of the recently deceased, at what point might we be able to reverse sudden deaths? Could we revive soldiers who bleed out on the battlefield? Could we stock hospitals and nursing homes with buckets of the stuff to resuscitate patients? Should every future American household keep some on hand in the event of a terrible accident?

These questions thrust us into the ethical realm and invoke spooky references to "The Monkey's Paw," Pet Sematary, and any number of stories about the dark side of trying to design an escape hatch from mortality. Perhaps, as this technology improves, that debate is on its way. But for millions of people who have lost loved ones to, say, a sudden heart attack or stroke, it's not remotely dystopian to imagine an injection that could reverse tragedies long considered irreversible....

The Power to Synthesize Life (Kind Of)
This summer, scientists grew an embryo in a lab without the use of sperm, or eggs, or a womb. It happened to be that of a mouse. But the species is of secondary importance.... Some scientists I consulted for this project said that the results, which were published this year in the science journal Cell, were the most important scientific breakthrough of 2022.

Scientists are not close to turning stem cells into human babies that make their first gasping cries in antiseptic laboratories. But this work does suggest a major leap forward in our ability to grow synthetic organs and more closely research the relationship between embryonic mutations and developmental diseases. As Paul Tesar, a developmental biologist at Case Western Reserve University School of Medicine, told Stat, "As soon as the science starts to move into a place where it's feasible to go from a stem cell population in a Petri dish all the way through to organ development, it's a pretty wild and remarkable time."
The article also notes that NuScale's small nuclear reactors received approval from the U.S. Nuclear Regulatory Commission, and "could be running by the end of the decade." Meanwhile, the start-up Quaise is working on drilling technology "that can vaporize granite with a highly concentrated beam of radio-frequency power. If such a technology became widely available, deep drilling would be commonplace and geothermal energy would be accessible on just about any patch of land. It would be as though humankind conceived of a magic wand that, waved across the Earth, makes any square mile as energy-rich as an oil-gushing stretch of Texas or Saudi Arabia."

The article also suggests one more possibility for the future. "Decades from now, millions of people may actually prefer the consistency and taste of meat that didn't come from an animal, because they'll know what they're buying when a cultivated rib eye is as consistent as an electrical gadget."

An anonymous reader quotes a report from CNBC: Former Theranos chief operating officer and president Ramesh "Sunny" Balwani was sentenced to nearly 13 years in prison Wednesday for fraud, after the unraveling of the blood-testing juggernaut prompted criminal charges in California federal court against both Balwani and Theranos founder Elizabeth Holmes, who on Nov. 18 was sentenced to more than 11 years in prison.

During the sentencing hearing, attorneys for Balwani attempted to pin the blame on Holmes, telling U.S. District Court Judge Edward J. Davila that "decisions were made by Elizabeth Holmes." Davila had set a sentencing range of 11 years plus 3 months to 14 years, but prosecutors today sought a 15-year sentence given his "significant" oversight role at Theranos' lab business. The final guideline sentence was 155 months, plus three years of probation. Davila set a Mar. 15, 2023, surrender date. [...] Balwani's sentencing in federal court marks the end of the Theranos saga, which enthralled the public and prompted documentary films and novel treatments.

Marc Tessier-Lavigne is president of Stanford University. He's also "the subject of a university investigation," reports SFGate, "following a report from the school's newspaper, the Stanford Daily, that he committed scientific research misconduct" in papers he co-authored years ago which may contain altered images.

More from the Washington Post: The university launched the inquiry after the Stanford Daily, a campus newspaper, reported that a well-known research journal was looking into concerns raised about a 2008 paper co-authored by Marc Tessier-Lavigne. The Daily reported that in addition to the paper in the European Molecular Biology Organization Journal, there were questions about other published research.

Some of those complaints were first made many years ago, and Tessier-Lavigne had tried to correct papers at one journal in 2015, according to its editor.... Tessier-Lavigne said in a statement that he supports the inquiry. "Scientific integrity is of the utmost importance both to the university and to me personally," Tessier-Lavigne said. "I support this process and will fully cooperate with it, and I appreciate the oversight by the Board of Trustees...."

Elisabeth Bik, who had been a staff scientist at Stanford doing postdoctoral microbiology research until 2016 and is now a well-known research integrity consultant who specializes in photographic images, said she heard about the questions about some papers of which Tessier-Lavigne is one of the authors a few years after they were first raised, and identified additional possible problems.

Most appeared to be minor concerns, and they could have been honest mistakes, she said. This week, Bik said, she spotted a more troubling instance in a paper from 1999 with multiple authors where it appeared photos had been altered, which she said was suggestive of copying and pasting.
The Los Angeles Times describes Tessier-Lavigne as "a neuroscientist and biotech entrepreneur widely known for his Alzheimer's research" who "has authored or co-authored about 300 scientific papers."

"Get ready: Neurotechnology is coming to the workplace," claims IEEE Spectrum: Neural sensors are now reliable and affordable enough to support commercial pilot projects that extract productivity-enhancing data from workers' brains.

These projects aren't confined to specialized workplaces; they're also happening in offices, factories, farms, and airports. The companies and people behind these neurotech devices are certain that they will improve our lives. But there are serious questions about whether work should be organized around certain functions of the brain, rather than the person as a whole.

To be clear, the kind of neurotech that's currently available is nowhere close to reading minds. Sensors detect electrical activity across different areas of the brain, and the patterns in that activity can be broadly correlated with different feelings or physiological responses, such as stress, focus, or a reaction to external stimuli. These data can be exploited to make workers more efficient — and, proponents of the technology say, to make them happier. Two of the most interesting innovators in this field are the Israel-based startup InnerEye, which aims to give workers superhuman abilities, and Emotiv, a Silicon Valley neurotech company that's bringing a brain-tracking wearable to office workers, including those working remotely....

EEG has recently broken out of clinics and labs and has entered the consumer marketplace. This move has been driven by a new class of "dry" electrodes that can operate without conductive gel, a substantial reduction in the number of electrodes necessary to collect useful data, and advances in artificial intelligence that make it far easier to interpret the data. Some EEG headsets are even available directly to consumers for a few hundred dollars.

For the first time, America's Food and Drug Administration has "approved a treatment that can delay the onset of Type 1 diabetes," reports ABC News: Teplizumab, a monoclonal antibody that will be marketed under the brand name Tzield from pharmaceutical companies ProventionBio and Sanofi, is administered through intravenous infusion. The injection was shown in clinical trials to delay onset of insulin-dependent Type 1 diabetes for patients with autoantibody markers of early risk by over two years, with hopes for some that it can delay onset even longer.... Tzield was approved to delay the onset of stage 3 Type 1 diabetes in adults and children ages 8 and up who currently have stage 2 Type 1 diabetes.

The medication is thought to slow down the body's attack on its own insulin-producing cells and thus give people more time before they become dependent on pharmaceutical insulin. Tzield is not suitable for people with insulin-dependent Type 1 diabetes, people who are pre-Type 2 diabetics or those with type 2 diabetes. "This approval is a watershed moment for the treatment and prevention of type 1 diabetes," said Dr. Mark S. Anderson, director of the University of California San Francisco Diabetes Center. "Until now, the only real therapy for patients has been a lifetime of insulin replacement. This new therapy targets and helps to halt the autoimmune process that leads to the loss of insulin...."

Studies have shown that 75% of people with these diagnostic markers usually become insulin-dependent within five years and nearly 100% at some point in their lifetime.
ABC News also shares this quote from Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research. "The drug's potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease."

Theranos founder Elizabeth Holmes was sentenced Friday in a federal court to 135 months, more than 11 years in prison following her conviction on four counts of criminal fraud. The court found she deceived investors, including News Corp.'s Rupert Murdoch and a host of other luminaries, about the efficacy of Theranos' blood-testing technology. CNBC reports: Holmes cried while speaking to the court ahead of her sentencing. "I loved Theranos. It was my life's work," Holmes said. "My team meant the world to me. I am devastated by my failings. I'm so so sorry. I gave everything I had to build my company." Her defense team argued she should face a maximum sentence of 18 months, according to court filings.

The Wall Street Journal first broke the story of how Theranos' blood-testing technology was struggling to meet expectations in 2015. Whistleblowers and other witnesses came forth to provide detailed accounts of how Holmes and former operating chief Ramesh "Sunny" Balwani deceived patients, partners, investors and employees about the company's progress and the capabilities of its technology. "Thank you for having me. Thank you for the courtesy and respect you have shown me," she said Friday. "I have felt deep pain for what people went through because I failed them. To investors, patients, I am sorry." Prosecutors sought a 15 year sentence for the pregnant 38-year-old former billionaire and Silicon Valley celebrity. Developing...

"Federal prosecutors are asking a judge to sentence Elizabeth Holmes to 15 years in prison," reports the Guardian, "and require the Theranos founder to pay $800m in restitution, according to court documents filed on Friday." A jury found Holmes guilty in January of four counts of investor fraud and conspiracy. Her sentencing is scheduled for 18 November, and she faces a maximum 20 years in prison. Prosecutors argued that "considering the extensiveness of Holmes's fraud", their recommended sentencing would "reflect the seriousness of the offenses, provide for just punishment for the offenses, and deter Holmes and others".

Holmes's lawyer argued in documents filed on Thursday that the ex-Theranos boss should not be sentenced to prison at all and, at most, should receive 18 months of house arrest. The court filings argued that Holmes had been made a "caricature to be mocked and vilified" by the media over the years, though she is a caring mother and friend.

"Ms Holmes is no danger to the public," Holmes's lawyer said in the court documents. "She has no criminal history, has a perfect pretrial services compliance record, and is described by the people who know her repeatedly as a gentle and loving person who tries to do the right thing."

An anonymous reader quotes a report from Motherboard: The Queensland, Australia police have used DNA phenotyping for the first time ever in hopes of leading to a breakthrough for a 1982 murder. The department partnered with a U.S.-based company called Parabon NanoLabs to create a profile image of the murder suspect, a Caucasian man with long blonde hair. Police claim that this image was generated using blood samples found at the scene of the murder of a man from 40 years ago; according to the Australian Broadcasting Corporation this is the first time "investigative genetic genealogy" has been used in Queensland.

This image does not factor in any environmental characteristics, such as tattoos, facial hair, and scars, and cannot determine the age or body mass of the suspect. However, Queensland investigators have published the image online and are offering a $500,000 reward and indemnity from prosecution to anyone who might have information about the suspect. The image is a vague rendering of a man that does not provide any more information than the sketch that the department already has of the suspect. This further perpetuates the hyper-surveillance of any man who resembles the image. Parabon NanoLabs has already been criticized by criminal justice and privacy experts for disseminating images that implicate too broad a pool of suspects.

The Queensland police department said that the DNA sample from the case generated a genealogy tree of "15,000 'linked' individuals" and they have not been able to find a close match yet. Instead of facing the possibility that DNA phenotyping may not be an effective tool for narrowing down a suspect, the police department's strategy is to ask the public for their DNA samples. Criminologist Xanthe Mallett said in a press release that to help police find a match, people can "opt-in" to share their own DNA samples with investigators through DNA services such as Family Tree and GEDMatch. "Many members of the public that see this generated image will be unaware that it's a digital approximation, that age, weight, hairstyle, and face shape may be very different, and that accuracy of skin/hair/eye color is approximate," said Callie Schroeder, the Global Privacy Counsel at the Electronic Privacy Information Center.

Ugur Sahin and and Özlem Türeci. The BBC calls them "the husband and wife team behind one of the most successful Covid vaccines" — the couple who co-founded the German biotech company BioNTech in 2008, "exploring new technology involving messenger RNA to treat cancer."

And though they partnered with Pfizer to ues the same approach for their Covid vaccine, "Now the doctors are hopeful it could lead to new treatments for melanoma, bowel cancer and other tumour types." BioNTech has several trials in progress, including one where patients are given a personalised vaccine, to prompt their immune system to attack their disease. The mRNA technology being used works by sending an instruction or blueprint to cells to produce an antigen or protein. In Covid this antigen is part of the spike protein of the virus. In cancer it would be a marker on the surface of tumour cells. This teaches the immune system to recognise and target affected cells for destruction.

Speaking on the BBC's Sunday with Laura Kuenssberg, Prof Tureci said: "mRNA acts as a blueprint and allows you to tell the body to produce the drug or the vaccine... and when you use mRNA as a vaccine, the mRNA is a blueprint for the 'wanted poster' of the enemy — in this case cancer antigens which distinguish cancer cells from normal cells."

Harnessing the power of mRNA to produce vaccines was unproven until Covid. But the success of mRNA vaccines in the pandemic has encouraged scientists working with the technology in cancer.
The Guardian notes that the couple said cancer-targetting vaccines could be available "before 2030", though Özlem Türeci warns that "As scientists we are always hesitant to say we will have a cure for cancer. We have a number of breakthroughs and we will continue to work on them." BioNTech was working on mRNA cancer vaccines before the pandemic struck but the firm pivoted to produce Covid vaccines in the face of the global emergency. The firm now has several cancer vaccines in clinical trials.

Long-time Slashdot reader mspohr shares a report from the Boston Globe's health-news site STAT: The scientist flicked on a laser, filling the rat's brain with blue light. The rodent, true to its past two weeks of training, scampered across its glass box to a tiny spout, where it was duly rewarded with a drink of water. From the outside, this would appear to be a pretty run-of-the-mill neuroscience experiment, except for the fact that the neurons directing the rat to its thirst-quenching reward didn't contain any rat DNA. Instead, they came from a human "mini-brain" — a ball of human tissue called an organoid — that researchers at Stanford University School of Medicine had grown in a lab and implanted in the rodent's cortex months before.

The experiment — part of a study published Wednesday in Nature — is the first describing human neurons influencing another species' behavior. The study also showed that signals could go the other way; tendrils of human neurons mingled with the rodent brain cells and fired in response to air rustling the rats' whiskers.

The advance opens the door to using such human-rodent chimeras to better understand how the human brain develops and what goes wrong in neurological and psychiatric conditions such as schizophrenia, autism, and epilepsy. When the Stanford scientists implanted organoids grown from the cells of patients with a severe genetic brain disorder, they could watch the neurons develop abnormally with unprecedented clarity.

"This paper really pushes the envelope," said neuroscientist Tomasz Nowakowski, of the University of California, San Francisco, who uses brain organoids in his research on neurodevelopmental disorders but was not involved in the new work. "The field is desperate for more experimental models. And what's really important about this study is it demonstrates that brain organoids can complete their maturation trajectory when transplanted. So it really expands our toolkit for asking more nuanced questions about how genetic mutations lead to behavioral disorders."
It's an example of how stem cells have revolutionized brain research. By "doing their experiments in very young rats whose cortexes are not yet saturated with synapses," the article points out, the researchers "found that the human neurons easily integrated into the animals' rapidly expanding circuitry, which provided them with the stimulation they needed to push past previous developmental barriers."